בייאטה 5 מק"ג
Country: Iżrael
Lingwa: Ebrajk
Sors: Ministry of Health
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
EXENATIDE 250 MCG/ML
Disponibbli minn:
ASTRA ZENECA ISRAEL LTD
Kodiċi ATC:
A10BX04
Għamla farmaċewtika:
SOLUTION FOR INJECTION
Rotta amministrattiva:
S.C
Manifatturat minn:
LILLY PHARMA FERT. & DISTRIB. GmbH & Co. KG
Grupp terapewtiku:
EXENATIDE
Indikazzjonijiet terapewtiċi:
Byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.Byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.
Data ta 'l-awtorizzazzjoni:
2013-01-01
